SequelSEC

ENDRA Life Sciences Inc. NDRA

Electromedical & Electrotherapeutic Apparatus · CIK 0001681682 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2020-12-31
Operating income
Unavailable
Fiscal year ended 2020-12-31
Free cash flow
Unavailable
Fiscal year ended 2020-12-31

This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ENDRA Life Sciences Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

ENDRA Life Sciences Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
RevenueUnavailable$0$0$0$0$0$0$0$6.17K$6.85K
Cost of revenueUnavailableUnavailable$0$0$0Unavailable$0$0$0Unavailable
Gross profitUnavailable$0$0$0$0$0$0$0$6.17K$3.76K
Operating incomeUnavailable-$3.13M-$2.64M-$2.33M-$2.75M-$2.00M-$2.36M-$1.82M-$2.84M-$2.30M
Net incomeUnavailable-$4.81M-$3.41M-$2.33M-$2.75M-$2.37M-$2.76M-$1.85M-$2.83M-$2.29M
Research & developmentUnavailable$2.03M$1.47M$1.30M$1.77M$1.05M$1.16M$839.76K$1.67M$1.36M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailable-$4.81M-$3.41M-$2.33M-$2.75M-$2.37M-$2.76M-$1.85M-$2.83M-$2.29M
Income tax expenseUnavailable$0$0$0$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailable$1.10M$1.17M$1.02M$973.72K$951.83K$905.06K$983.31K$1.17M$940.33K
General & administrativeUnavailable$935.34K$1.07M$932.02K$916.90K$909.90K$832.88K$941.96K$1.07M$873.13K
Selling & marketingUnavailable$167.07K$100.20K$88.34K$56.82K$41.93K$72.18K$41.36K$107.18K$67.20K

Balance

ENDRA Life Sciences Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$8.76M$7.18M$3.62M$3.19M$4.64M$7.22M$1.29M$3.05M$3.69M$6.12M
Current assets$8.21M$6.54M$2.98M$2.95M$4.38M$6.95M$998.61K$2.83M$3.46M$5.88M
Total liabilities$1.60M$2.42M$2.21M$1.37M$835.23K$974.58K$1.75M$1.10M$860.20K$848.21K
Current liabilities$986.66K$2.07M$1.85M$1.37M$835.23K$974.58K$1.07M$751.38K$860.20K$848.21K
Total equity incl. NCI$7.17M$4.76M$1.40M$1.82M$3.80M$6.25M-$457.61K$1.94M$2.83M$5.28M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$589.62K$113.44K$127.83K$74.28K$74.28K$59.44K$0$279.21K$245.96K$191.68K
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$0$12.28K$11.77K$11.77K$6.85K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$402.91K$1.28M$646.88K$1.01M$553.00K$631.47K$750.58K$462.59K$813.72K$780.26K

Cash flow

ENDRA Life Sciences Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Operating cash flowUnavailable-$1.91M-$2.48M-$1.66M-$2.54M-$1.90M-$1.47M-$1.88M-$2.45M-$1.38M
Capital expendituresUnavailable$38.36K$0-$1$5.24K$0$100.00K$0$0$0
Investing cash flowUnavailable-$38.36K$0$1-$5.24K$0-$100.00K$0$0$0
Financing cash flowUnavailable$5.84M$2.49M$0$0$7.74M$0$935.30K$0$0
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailable$0$0$0UnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$20.90K$19.93K$20.11K$19.63K$20.07K$18.04K$14.86K$15.34K$15.36K

Derived

ENDRA Life Sciences Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Free cash flowUnavailable-$1.95M-$2.48MUnavailable-$2.55M-$1.90M-$1.57M-$1.88M-$2.45M-$1.38M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable100.0%55.0%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-45960.8%-33526.6%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-39713.2%-20081.5%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio8.32x3.15x1.61x2.16x5.24x7.13x0.93x3.77x4.03x6.93x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable-100.0%-100.0%-100.0%-100.0%Unavailable-98.7%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-45761.3%-33498.4%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable27029.9%19854.1%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%0.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NDRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.